SpyGlass Pharma, Inc.

SGP Nasdaq SEC CIK 1778922
Follow SpyGlass Pharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$24.3M −147.1% vs same quarter last year
EPS, diluted −$0.73 +83.9% vs same quarter last year
Operating cash flow −$16M −81.2% vs same quarter last year
Operating income −$26.2M −136.4% vs same quarter last year
Net income by quarter
−$8.8M
−$8.7M
−$9.8M
−$12.6M
−$13.8M
−$19.9M
−$24.3M
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing